Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2017

View Archived Issues

Novel Drosophila FXS model as promising screening strategy for therapeutic discovery

EpimAb Biotherapeutics and WuXi Biologics collaborate to advance development of EMB-01

Advaxis and BMS to test ADXS-DUAL plus Opdivo in metastatic cervical cancer

Sylentis initiates phase III HELIX study of SYL-1001as treatment of dry eye syndrome

Researchers design a novel antibody-powered DNA-based nanomachine

ProQR Therapeutics receives FDA fast track designation for QR-110

EMA's COMP recommends orphan medicinal product designation for Catalyst Biosciences' CB-2679d

Alnylam's givosiran receives FDA breakthrough therapy designation

IMIDomics enters strategic collaboration with Celgene

Eisai and Johns Hopkins announce extension of their drug discovery collaboration

Phase III HALO study of fremanezumab in migraine meets endpoints

FDA grants rare pediatric disease designation to Amicus' SD-101 for epidermolysis bullosa

New model reveals role of IRAK-M in rhinovirus infection

AstraZeneca presents serine-protein kinase ATM inhibitors

FDA grants priority review to Vyxeos NDA for AML

FDA approves Novo Nordisk's Rebinyn for hemophilia B

Roche divulges equilibrative nucleoside transporter 1 inhibitors

MabVax enters research agreement with Memorial Sloan Kettering for CAR T-cell therapeutics

Simon Fraser University and collaborator discover MRSA pyruvate kinase inhibitors

FDA approves first topical ocular formulation of cetirizine

R-Pharm CJSC presents MEK1/2 inhibitors

Phase III study of elafibranor in NASH recommended to continue by DSMB

Servier and ILTOO Pharma enter license agreement for ILT-101

Janssen Pharmaceutica discloses PDE2 inhibitors

FDA, EMA accept Pfizer's applications seeking to expand approved use of Sutent

Review committee recommends dose escalation in MEI Pharma's phase I study of ME-401

Minerva Neurosciences to amend MIN-202 agreement with Janssen

First patient enters Oncology Venture's phase I/II study of APO-010

Transient improvement seen in children with autism treated with suramin

FAM46A mutations found to cause a form of osteogenesis imperfecta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...